Physician profile
William Kellogg
NPI 1265490643
$21,033.45
in general payments reported to CMS, 2019-2025
75 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,660 · 2020: $3,710 · 2021: $4,092 · 2022: $3,985 · 2023: $3,501 · 2024: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,565 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,564.92 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,269.96 | 2019-2024 | Enhertu, Calquence, Lynparza |
| Novartis Pharmaceuticals Corporation | $1,693.35 | 2019-2024 | |
| Amgen INC. | $1,640.50 | 2019-2023 | Kyprolis, Blincyto, Nplate |
| Merck Sharp & Dohme LLC | $903.95 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $770.32 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $732.61 | 2019-2024 | Perjeta, Tecentriq, Phesgo |
| E.R. Squibb & Sons, L.L.C. | $688.67 | 2019-2024 | Opdivo, Opdualag |
| Seagen INC. | $679.17 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Exelixis INC. | $663.04 | 2019-2024 | Cabometyx |
| Astellas Pharma US INC | $658.86 | 2019-2024 | Xospata, Xtandi, Padcev |
| Celgene Corporation | $613.23 | 2019-2024 | Pomalyst, Reblozyl, Opdualag |
| Pfizer INC. | $594.13 | 2019-2024 | |
| Genzyme Corporation | $512.63 | 2019-2023 | |
| Incyte Corporation | $500.82 | 2019-2024 | Jakafi |
| Pharmacyclics LLC, An Abbvie Company | $495.06 | 2019-2023 | Imbruvica |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kellogg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.